GlaxoSmithKline

Opens access to Asia and Africa – potential to save hundreds of thousands of lives

June 5, 2009 -- London UK -- The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline Biologicals’ vaccine against rotavirus, Rotarix™.Additionally, the WHO's Strategic Advisory Group of Experts (SAGE) also recommended that rotavirus vaccination be included in all national immunisation programmes. Together, these WHO decisions open the door to making rotavirus vaccines available to children worldwide.    » read more »

June 2, 2009 -- London, UK -- GlaxoSmithKline (NYSE: GSK) and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines. The deal includes three of Concert’s research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert’s pipeline.

Concert will also provide GSK with deuterium-modified versions of three GSK pipeline compounds for GSK to develop.    » read more »

22 May 2009 -- GSK announced today that the US Department of Health and Human Services (HHS) has placed initial orders for A (H1N1) influenza vaccine antigen and the company’s proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts.

GSK manufactures both a traditional vaccine antigen, which will be made from the recently isolated A (H1N1) influenza strain, as well as an adjuvant system. An adjuvant system can be added to the antigen at time of administration.

GSK expects to fill the US adjuvant order within the next few months. The first doses of the vaccine antigen are expected to be available four to six months after the company receives the H1N1 seed strain, subject to regulatory approval. The new vaccine will be tested in clinical trials.    » read more »

Jerusalem, Israel, July 23, 2008 -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial shipment of its generic version of Lamictal® (Lamotrigine) Tablets, 25mg, 100 mg, 150 mg, and 200 mg. Teva's Lamotrigine tablets are the AB-rated generic equivalent of GlaxoSmithKline's Lamictal® Tablets, and are indicated as adjunctive therapy in the treatment of partial seizures and the generalized seizures of Lennox-Gastaut syndrome, for conversion to monotherapy in adults with partial seizures who are taking certain other antiepileptic agents, and for maintenance treatment of Bipolar I Disorder.    » read more »

SAN FRANCISCO, 05/19/2008 – Motorola, Inc., Siemens Corp. and GlaxoSmithKline will collectively pay a $500,000 civil penalty for system failures that led to the release of trichloroethylene (TCE) into the public drinking water system in Scottsdale, Ariz., the U.S. Environmental Protection Agency (EPA) and the Department of Justice announced today.

The settlement resolves violations of the North Indian Bend Wash consent decree, filed in 2003, which occurred when TCE above contamination limits was released from the Miller Road Treatment Facility on two separate occasions, in October 2007 and January 2008.    » read more »

Glaxo-Smith Kline falsely priced Medicaid-covered drugs, repays Texas $1.4 million

November 16, 2007 -- AUSTIN – Texas Attorney General Greg Abbott today settled a fraudulent drug pricing case with pharmaceutical giant Glaxo-Smith Kline, its parent company, SmithKline Beecham Corp., and a subsidiary. Under the settlement, the defendants agreed to repay almost $1.4 million for charging the state inflated prices for three prescription drugs from 1994 to 2002.    » read more »

Oct. 5, 2007 -- A selection of sketchbooks from artists Walter Shirlaw, Isabel Bishop, Leon Kroll, Frank Stella, Lowell Nesbitt and others is presented in the new exhibition "Sketchbooks from the Archives of American Art" Oct. 5 to Jan. 6, 2008, in the Archives of American Art's Lawrence A. Fleischman Gallery.    » read more »

Study finds Avandia increases risk of heart attack, death

WASHINGTON (May 25, 2007) - A coalition of scientific, public health and consumer organizations today issued a letter urging the Food and Drug Administration (FDA) to exclude scientists with financial ties to GlaxoSmithKline from a panel reviewing the safety of the pharmaceutical giant's popular type 2 diabetes drug, Avandia.    » read more »